Trial Profile
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary) ; Prednisolone acetate
- Indications Ocular inflammation
- Focus Registrational; Therapeutic Use
- Sponsors KALA BIO
- 02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO.
- 08 Jan 2019 Status changed from recruiting to discontinued.
- 30 Jul 2018 New trial record